

# **ALK Positive, Inc.**

**Financial Statements  
December 31, 2025**

**ALK Positive, Inc.**

**Financial Statements**

**December 31, 2025**

Table of Contents

	<u>Page</u>
Independent Auditor's Report	1
Financial Statements:	
Statement of Financial Position	3
Statement of Activities	4
Statement of Functional Expenses	5
Statement of Cash Flows	6
Notes to the Financial Statements	7

*Independent Auditor's Report*

To the Board of Directors  
ALK Positive, Inc.

***Opinion***

We have audited the financial statements of ALK Positive, Inc. (a nonprofit corporation, the "Organization"), which comprise the statement of financial position as of December 31, 2025, and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Organization as of December 31, 2025, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

***Basis for Opinion***

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

***Responsibilities of Management for the Financial Statements***

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.

To the Board of Directors  
ALK Positive, Inc.

***Auditor's Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

*Ciuni + Panichi, Inc.*

Cleveland, Ohio  
June 15, 2026

# ALK Positive, Inc.

## Statement of Financial Position

December 31, 2025 (with comparative totals for 2024)

	<u>Assets</u>	
	<u>2025</u>	<u>2024</u>
Current assets:		
Cash and cash equivalents	\$ 1,780,753	\$ 1,547,913
Accounts receivable	480	4,000
Contributions receivable	166,408	588,902
Investments	4,765,386	3,014,436
Advance payment on conditional grant	-	300,000
Prepaid expenses	54,597	51,071
Total current assets	<u>6,767,624</u>	<u>5,506,322</u>
Other assets:		
Website, net	85,028	107,870
Trademark	3,312	3,312
Total other assets	<u>88,340</u>	<u>111,182</u>
Total assets	\$ <u>6,855,964</u>	\$ <u>5,617,504</u>
	<u>Liabilities and Net Assets</u>	
Current liabilities:		
Accounts payable	\$ 101,679	\$ 73,476
Accrued payroll liabilities	1,536	9,868
Other accrued expenses	14,352	9,595
Grants payable	265,445	-
Total current liabilities	<u>383,012</u>	<u>92,939</u>
Net assets:		
Without donor restrictions	5,497,789	3,576,304
With donor restrictions	975,163	1,948,261
Total net assets	<u>6,472,952</u>	<u>5,524,565</u>
Total liabilities and net assets	\$ <u>6,855,964</u>	\$ <u>5,617,504</u>

The accompanying notes are an integral part of these financial statements

## ALK Positive, Inc.

### Statement of Activities

**For the year ended December 31, 2025 (with comparative totals for 2024)**

	2025			2024 Total
	Without Donor Restrictions	With Donor Restrictions	Total	
Revenue and other support:				
Contributions	\$ 2,529,233	\$ 1,136,308	\$ 3,665,541	\$ 3,574,743
Investment return, net	169,153	-	169,153	120,478
Ticket sales	22,946	-	22,946	8,938
Miscellaneous income	11,897	-	11,897	10,110
Net assets released from restrictions	2,109,406	(2,109,406)	-	-
Total revenue and other support	4,842,635	(973,098)	3,869,537	3,714,269
Expenses:				
Program services	2,687,933	-	2,687,933	1,662,869
Supporting services:				
Management and general	183,244	-	183,244	129,680
Fundraising	49,973	-	49,973	85,950
Total expenses	2,921,150	-	2,921,150	1,878,499
Change in net assets	1,921,485	(973,098)	948,387	1,835,770
Net assets, beginning of year	3,576,304	1,948,261	5,524,565	3,688,795
Net assets, end of year	\$ 5,497,789	\$ 975,163	\$ 6,472,952	\$ 5,524,565

The accompanying notes are an integral part of these financial statements

# ALK Positive, Inc.

## Statement of Functional Expenses

For the year ended December 31, 2025 (with comparative totals for 2024)

	Program Services			Supporting Services			2025 Total	2024 Total
	Program	Links for Lungs	Total	Management and General	Fundraising	Total		
Salaries, payroll taxes, and benefits	\$ 419,568	\$ -	\$ 419,568	\$ 62,434	\$ 43,937	\$ 106,371	\$ 525,939	\$ 513,422
Program supplies	426,733	-	426,733	-	-	-	426,733	263,177
Research grants	1,494,518	79,000	1,573,518	-	-	-	1,573,518	852,344
Travel	63,201	-	63,201	-	399	399	63,600	40,240
Bank charges	-	-	-	44,703	-	44,703	44,703	28,581
Professional services	6,002	-	6,002	813	63	876	6,878	37,832
Accounting	-	-	-	57,782	-	57,782	57,782	47,457
Amortization	27,209	-	27,209	850	283	1,133	28,342	-
Awards	1,459	-	1,459	141	15	156	1,615	-
Equipment and software	67,330	375	67,705	1,652	331	1,983	69,688	26,762
Second Opinion program	6,362	-	6,362	-	-	-	6,362	7,477
Patient services	12,497	-	12,497	-	-	-	12,497	250
Insurance	4,647	-	4,647	699	48	747	5,394	4,761
Interest	-	-	-	800	-	800	800	463
Licenses and fees	22,896	-	22,896	716	239	955	23,851	15,319
Marketing and promotion	-	-	-	-	3,879	3,879	3,879	-
Meetings and events	6,807	32,295	39,102	-	-	-	39,102	7,599
Office supplies	383	-	383	12	4	16	399	-
Postage	3,269	-	3,269	751	31	782	4,051	8,613
Dues and subscriptions	7,544	-	7,544	8,251	40	8,291	15,835	6,467
Printing	292	-	292	1	-	1	293	9,176
Telephone and internet	770	-	770	130	660	790	1,560	2,511
Miscellaneous	-	-	-	3,377	-	3,377	3,377	5,724
Website	4,224	552	4,776	132	44	176	4,952	324
<b>Total expenses</b>	<b>\$ 2,575,711</b>	<b>\$ 112,222</b>	<b>\$ 2,687,933</b>	<b>\$ 183,244</b>	<b>\$ 49,973</b>	<b>\$ 233,217</b>	<b>\$ 2,921,150</b>	<b>\$ 1,878,499</b>

The accompanying notes are an integral part of these financial statements

# ALK Positive, Inc.

## Statement of Cash Flows

For the year ended December 31, 2025 (with comparative totals for 2024)

	<u>2025</u>	<u>2024</u>
Cash flows from operating activities:		
Change in net assets	\$ 948,387	\$ 1,835,770
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Amortization	28,342	-
Net realized and unrealized loss (gain) on investments	955	(3,237)
Decrease (increase) in operating assets and liabilities:		
Accounts receivable	3,520	(1,673)
Contributions receivable	422,494	(442,439)
Advance payment on conditional grant	300,000	-
Prepaid expenses	(3,526)	(24,847)
Accounts payable	28,203	(44,409)
Accrued payroll liabilities	(8,332)	(6,724)
Other accrued expenses	4,757	7,629
Grants payable	265,445	(875,000)
Net cash provided by operating activities	<u>1,990,245</u>	<u>445,070</u>
Cash flows from investing activities:		
Purchases of investments	(1,751,905)	(264,749)
Website development costs	(5,500)	(63,495)
Net cash used by investing activities	<u>(1,757,405)</u>	<u>(328,244)</u>
Net increase in cash and cash equivalents	232,840	116,826
Cash and cash equivalents, beginning of year	<u>1,547,913</u>	<u>1,431,087</u>
Cash and cash equivalents, end of year	<u>\$ 1,780,753</u>	<u>\$ 1,547,913</u>

The accompanying notes are an integral part of these financial statements

# ALK Positive, Inc.

## Notes to Financial Statements

December 31, 2025

### Note 1: Nature of Activities

ALK Positive, Inc. (the “Organization”) is a patient driven 501c(3) nonprofit corporation providing support, education and research funding to change the future for ALK-positive cancer patients. ALK-positive cancer is estimated to occur in approximately 75,000-175,000 people worldwide every year. Although the vast majority of cases occur as lung cancer, the ALK gene can also originate in many cancer types. The median age for ALK-positive lung cancer patients at diagnosis is about 50 years with many in their forties, thirties and even younger. Approximately 55% of ALK-positive patients are female and the disease occurs with people of all races.

In 2017, some ALK-positive cancer patients and caregivers formed the Outreach Management Group to partner with the LUNGeivity Foundation in order to raise funds for cancer research. In 2018, the partnership was formalized into a joint fundraising and research agreement with both LUNGeivity and the GO2 Foundation for Lung Cancer. From 2017 to 2021, the partnerships generated over \$4.7M in contributions and awarded \$2.8M in translational research grants with the purpose of improving ALK-positive cancer patient outcomes. By March 2021, the Outreach Management Group had incorporated and was recognized by the IRS as a 501c(3) non-profit organization called ALK Positive, Inc. During 2021-2022, another approximately \$3.4M in contributions was generously raised with research grants totaling approximately \$2.6M awarded. A Director of Research and Clinical Affairs and an Executive Director were hired in 2022. For 2023, contributions totaled approximately \$2.5M with research grants outlays of approximately \$2.3M, and a Development Manager was hired. For 2024, fundraising totaled approximately \$3.6M with research grants outlays of approximately \$852,000. A grant was made to the Break Through Cancer project, with an initial amount of \$500,000 as part of a \$2 million, 4-year commitment (Note 7). A Medical Team Project Manager was hired to support the work of the Director of Research and Clinical Affairs, as well as the Medical Committees described below. For 2025, fundraising totaled approximately \$3.6M with research grants outlays of approximately \$1.5M. A joint effort was made with the American Association for Cancer Research providing a grant to support the salary and benefits of a fellow working on understanding TKI-resistance in ALK-positive lung cancer.

The mission of the Organization as a patient-driven organization is to seek a cure for ALK-positive cancer and works to improve patients’ quality of life and life expectancy worldwide. As a patient-led organization reaching patients in over 70 countries, the organization offers patient research, education, resources and awareness programs to meet its mission objectives. The Organization is supported primarily by non-corporate contributions.

By far the most effective treatments for ALK-positive lung cancer are the oral ALK tyrosine kinase inhibitors (TKIs). There are now six FDA approved TKIs. While TKIs have improved the median overall survival from a few months to many years, ALK-positive lung cancers inevitably mutate and become resistant to all TKIs. The Organization initially created the Research Review Panel (committee) comprising volunteer ALK-positive cancer patients and caregivers to partner with other lung cancer organizations to review and award grants to the most promising ALK-positive cancer research projects to improve patient outcomes. Since 2022, the committee structure evolved to include:

- Research Acceleration Committee: Advocates with companies and establishes collaborative research programs.
- Clinical Trials Committee: Educates about clinical trials to increase enrollment rates.

# ALK Positive, Inc.

## Notes to Financial Statements

December 31, 2025

### Note 1: Nature of Activities (continued)

- Translational Investigations Group: Conducts in silico research and establishes collaborations to find new drug targets in ALK-positive cancer cells.
- Grant Review Committee: Contributes to RFP development, grantee selection, and grant oversight.

In 2025, these Medical Committees continued to expand their connections, collaborations and partnerships with academic institutions, pharmaceutical companies, biotechs and diagnostic companies to accelerate research for ALK-positive cancer. Also in 2025, Dr. Ken Culver was appointed as Executive Director and Medical Director to guide the Organization's strategy and research investments.

### Note 2: Summary of Significant Accounting Policies and Procedures

#### Organization

The accompanying financial statements include the activity of ALK Positive, Inc. and Links for Lungs Denver (LFL), an organization for which ALK Positive, Inc. serves as the fiscal sponsor.

#### Basis of Presentation

The Organization follows authoritative guidance issued by the Financial Accounting Standards Board (FASB) which established the FASB Accounting Standards Codification (ASC) as the single source of authoritative accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared on the accrual basis of accounting. Net assets and revenues, expenses, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, net assets of the Organization and changes therein are classified and reported as follows:

*Net Assets Without Donor Restrictions* – Net assets that are not subject to donor-imposed restrictions, whether due to time or purpose.

*Net Assets With Donor Restrictions* – Net assets whose use has been limited by a donor to a specific time period or purpose. When a restriction expires (that is, when a time restriction ends or purpose restriction is accomplished), net assets are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions.

#### Adopted Accounting Pronouncement

In July 2025, the FASB issued Accounting Standards Update (ASU) 2025-05, *Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets*. The objective of this ASU is to reduce complexities in applying the guidance in *Topic 326, Financial Instruments – Credit Losses*. On January 1, 2025, the Organization adopted this ASU. There was no impact on beginning net assets as a result of this implementation.

# ALK Positive, Inc.

## Notes to Financial Statements

December 31, 2025

### Note 2: Summary of Significant Accounting Policies and Procedures (continued)

#### Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

#### Cash and Cash Equivalents

The Organization considers all unrestricted highly liquid investments with an initial maturity of three months or less to be cash equivalents, except those amounts held in the investment portfolio for long-term purposes.

#### Contributions and Contributions Receivable

Contributions received are recorded as without donor restriction or with donor restriction depending on the existence and/or nature of any donor-imposed restrictions. Support received with no donor-imposed restrictions is reported as an increase in net assets without donor restrictions; support received with donor-imposed restrictions is reported as an increase in net assets with donor restrictions.

Contributions receivable represents amounts promised during the year but not received as of the statement of financial position date. The Organization estimates that all contributions receivable will be received in full during the following fiscal year and therefore, no provision for potentially uncollectible amounts is deemed necessary.

#### Investments

The Investments Topic of the ASC (ASC 320) requires that covered investments be reported in the statement of financial position at fair value with any realized and unrealized gains and losses reported in the statement of activities. Investment income and gains and losses on investments are reported as increases or decreases in net assets without donor restrictions unless a donor or law restricts their use.

Donated investments are reflected as contributions at their estimated fair values at date of receipt and are reported in the activity of net assets without donor restrictions unless restricted, either by law or explicit donor restriction, in which case they would be reported in the activity of net assets with donor restrictions.

Dividend and interest income and realized and unrealized gains and losses on investments are reflected as “investment return, net” on the accompanying statement of activities.

#### Website

The Organization has a website that is recorded at cost of \$113,370 and is amortized based on the straight-line method over its estimated useful life of 3 years. Amortization expense related to the website for the year ended December 31, 2025 was \$28,342. Accumulated amortization totaled \$28,342 at December 31, 2025.

# ALK Positive, Inc.

## Notes to Financial Statements

December 31, 2025

### Note 2: Summary of Significant Accounting Policies and Procedures (continued)

#### Website (continued)

Future amortization expense is as follows for the years ended December 31:

2026	\$	37,790
2027		37,790
2028		<u>9,448</u>
	\$	<u>85,028</u>

#### Trademark

The Organization has a trademark with an indefinite life and a cost basis of \$3,312. No impairment loss was recognized during the year ended December 31, 2025.

#### Revenue Recognition

The Organization identifies a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and collectability of consideration is probable.

Earned revenue sources include revenue from ticket sales for the Summit conference. Revenue from ticket sales is recognized over time, over the length of the conference.

There are multiple performance obligations included in each ticket sale, including conference entry, food, and merchandise. However, it was determined that it was not cost beneficial to segregate out these performance obligations, and all performance obligations are met during the fiscal year. As a practical expedient, the Organization may apply revenue recognition guidance to a portfolio of contracts with similar characteristics if the Organization reasonably expects the effects on the financial statements of applying this guidance to the portfolio would not differ materially from applying this guidance to the individual contracts (or performance obligations) within that portfolio. The Organization is taking the practical expedient approach, as contracts are very similar as it relates to each customer.

The Organization had \$22,946 of revenue recognized over time for the year ended December 31, 2025.

Receivables were \$480 and \$4,000 at December 31, 2025 and 2024, respectively. There were no contract assets or liabilities at December 31, 2025 and 2024.

#### Income Taxes

ALK Positive, Inc. is tax-exempt, under Section 501c(3) of the Internal Revenue Code of 1986. No provision for federal income taxes has been reported in the accompanying financial statements.

# ALK Positive, Inc.

## Notes to Financial Statements

December 31, 2025

### Note 2: Summary of Significant Accounting Policies and Procedures (continued)

#### Income Taxes (continued)

ALK Positive, Inc. accounts for income taxes in accordance with the “Income Taxes” topic of the FASB ASC (ASC 740). Uncertain income tax positions are evaluated at least annually by management. ALK Positive, Inc. classifies interest and penalties related to income tax matters as income tax expense in the accompanying financial statements. As of December 31, 2025, ALK Positive, Inc. has identified no uncertain income tax positions and has incurred no amounts for income tax penalties and interest for the year then ended.

ALK Positive, Inc. files its Federal Form 990 in the U.S. federal jurisdiction, and files state registrations for charitable solicitation purposes in 23 states.

#### Functional Expenses

For the year ended December 31, 2025, the costs of providing the various programs and other activities have been summarized on a functional basis in the statements of activities and functional expenses. Accordingly, certain costs have been allocated among the programs and supporting services benefited. Expenses are assigned directly to the program or functional area benefited. Costs that benefit multiple functional areas have been allocated across programs and other supporting services based on employee salary allocations.

#### Concentrations of Credit Risk

Financial instruments which potentially subject the Organization to concentrations of credit risk consist of cash, investments, and contributions receivable.

At various times during the year ended December 31, 2025, the Organization’s cash in bank balances may have exceeded the federally insured limits.

At December 31, 2025, approximately 21% of the Organization’s contributions receivable was due from one donor. For the year ended December 31, 2025, approximately 14% of the Organization’s contribution revenue was from one donor.

Though the market value of investments is subject to fluctuations on a daily basis, the Board of Directors believes that the investment mix is prudent for the long-term welfare of the Organization.

#### Subsequent Events

Management has evaluated subsequent events through June 15, 2026, the date the financial statements were available to be issued.

# ALK Positive, Inc.

## Notes to Financial Statements

December 31, 2025

### Note 3: Fair Value Measurements

In accordance with the “Fair Value Measurements” topic of the FASB ASC (ASC 820), the Organization uses a three-level fair value hierarchy that categorizes assets and liabilities measured at fair value based on the observability of the inputs utilized in the valuation. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own valuation assumptions. These inputs reflect management’s judgment about the assumptions that a market participant would use in pricing the asset, and are based on the best available information which has been internally developed.

The following table sets forth by level, within the fair value hierarchy, the Organization’s assets recorded at fair value:

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>2025</u>
Money market funds	\$ <u>4,765,386</u>	\$ <u>-</u>	\$ <u>-</u>	\$ <u>4,765,386</u>
	\$ <u>4,765,386</u>	\$ <u>-</u>	\$ <u>-</u>	\$ <u>4,765,386</u>

Investment return, net consisted of the following for the year ended December 31, 2025:

Net realized and unrealized loss	\$ (955)
Dividends and interest	<u>170,108</u>
Investment return, net	\$ <u>169,153</u>

### Note 4: Related-Party Transactions

The Organization received \$48,611 in contributions from employees and members of the Board of Directors during the year ended December 31, 2025. The Organization had outstanding contributions receivable due from employees and members of the Board of Directors of \$7,600 at December 31, 2025.

### Note 5: Net Assets with Donor Restrictions

Net assets with donor restrictions are available for the following purposes at December 31, 2025:

Research	\$ 500,880
Summit	356,426
Links for Lungs	80,712
Second Opinion	<u>37,145</u>
Total	\$ <u>975,163</u>

# ALK Positive, Inc.

## Notes to Financial Statements

December 31, 2025

### Note 5: Net Assets with Donor Restrictions (continued)

Net assets with donor restrictions were released from donor restrictions as follows during the year ended December 31, 2025:

Research	\$ 1,492,701
ALK Life Study	62,527
Summit	425,594
Links for Lungs	122,222
Second Opinion	<u>6,362</u>
Total	\$ <u>2,109,406</u>

### Note 6: Retirement Plan

Employees are eligible to participate in a 401(k) retirement plan after 90 days of employment. The Organization matches 100% of employee contributions up to 3% of the employee's gross wages. For the year ended December 31, 2025, the Organization incurred \$11,483 in matching expense.

### Note 7: Commitments and Contingencies

The Organization collaborates with various organization and universities to fund lung cancer research grants. Payments to these organizations are conditional upon meeting certain benchmarks in the grant. Due to their conditional nature, these commitments are not recorded in the financial statements of the Organization until the conditions of the grant are met.

During the year ended December 31, 2024, the Organization entered into a \$2,000,000 conditional agreement with Break Through Cancer. During the year ended December 31, 2024, some of the conditions on this grant were met, and \$500,000 was paid to Break Through Cancer. During the year ended December 31, 2025, additional conditions on this grant were met, and \$500,000 was paid to Break Through Cancer and reflected within research grants expense on the accompanying statement of functional expenses. The remaining \$1,000,000 is outstanding as a conditional promise at December 31, 2025.

During the year ended December 31, 2025, the Organization entered into a \$307,768 conditional agreement with the Dana Farber Cancer Institute (DFCI). During the year ended December 31, 2025, some conditions on this grant were met, and \$153,884 is reflected within research grants expense on the accompanying statement of functional expenses. This amount is also reflected within grants payable on the accompanying statement of financial position at December 31, 2025, and was paid to DFCI subsequent to year end. The remaining \$153,884 is outstanding as a conditional promise at December 31, 2025.

During the year ended December 31, 2025, the Organization entered into a \$287,490 conditional agreement with Regents of the University of California (UC). During the year ended December 31, 2025, some conditions on this grant were met, and \$171,081 is reflected within research grants expense on the accompanying statement of functional expenses. Of this amount, \$124,520 was paid to UC during the year ended December 31, 2025, and \$46,561 is also reflected within grants payable on the accompanying statement of financial position at December 31, 2025. The remaining \$116,409 is outstanding as a conditional promise at December 31, 2025.

# ALK Positive, Inc.

## Notes to Financial Statements

December 31, 2025

### Note 7: Commitments and Contingencies (continued)

During the year ended December 31, 2025, the Organization entered into a \$400,000 conditional agreement with Regents of the University of Michigan. During the year ended December 31, 2025, conditions on this grant were not met. The full \$400,000 is outstanding as a conditional promise at December 31, 2025.

During the year ended December 31, 2025, the Organization entered into a \$1,701,248 conditional agreement with Regents of the University of Michigan. During the year ended December 31, 2025, conditions on this grant were not met. The full \$1,701,248 is outstanding as a conditional promise at December 31, 2025.

### Note 8: Liquidity and Availability of Resources

The Organization's financial assets available within one year of December 31, 2025 for general expenditure are as follows:

Cash and cash equivalents	\$ 1,780,753
Accounts receivable	480
Contributions receivable	166,408
Investments	<u>4,765,386</u>
	6,713,027
Less: amounts unavailable for general expenditures within one year, due to:	
Restricted by donor – Links for Lungs	(15,000)
Restricted by donor – Second Opinion	<u>(30,000)</u>
	<u>(45,000)</u>
Total financial assets available within one year	\$ <u>6,668,027</u>

The Organization maintains a policy of structuring its financial assets to be available as its general expenditures, liabilities, and other obligations come due. The Organization's goal is generally to maintain financial assets to meet six months of operating expenses. Management considers donor restricted contributions that will be used within one year as part of its ordinary operations as being available for general expenditures.